Health News Articles
Excerpts of Key Health News Articles in Major Media


Below are many highly revealing one-paragraph excerpts of important health articles from the mainstream media. Links are provided to the full articles on major media websites. If any link should fail to function, click here. These health news articles are listed by order of importance. For the same articles by date posted to this list, click here. For the list by date of news article click here. By choosing to educate ourselves on these important issues and to spread the word, we can and will build a brighter future.



Note: For an index to revealing excerpts of media articles on several dozen engaging topics, click here.

Why do some with HIV not get sick?
2006-08-17, MSNBC News
http://msnbc.msn.com/id/14392345/

As many as one in 300 HIV patients never get sick and never suffer damage to their immune systems and AIDS experts said on Wednesday they want to know why. Most have gone unnoticed by the top researchers, because they are well, do not need treatment and do not want attention, said Dr. Bruce Walker of Harvard Medical School. But Walker and colleagues want to study these so-called "elite" patients in the hope that their cases can help in the search for a vaccine or treatments. So far Walker and colleagues have not been able to find out why certain people can live for 15 years and longer with the virus and never get ill. The AIDS virus usually kills patients within two years if they are not treated. Walker has tracked down 200 elite patients and has now joined up with other prominent AIDS researchers to find at least 1,000 "elites" in North America and as many as possible globally.




Donations tie drug firms and nonprofits
2006-05-28, Philadelphia Inquirer (Philadelphia's leading newspaper)
http://www.philly.com/mld/inquirer/living/health/14687073.htm

The American Diabetes Association...privately enlisted an Eli Lilly & Co. executive to chart its growth strategy. The National Alliance on Mental Illness...lobbies for treatment programs that also benefit its drug-company donors. The National Gaucher Foundation...gets nearly all its revenue from one drugmaker, Genzyme Corp. Many patient groups and drug companies maintain close, multimillion-dollar relationships while disclosing limited or no details about the ties. An Inquirer examination of six groups, each a leading advocate for patients in a disease area, found that the groups rarely disclose such ties when commenting or lobbying about donors' drugs. Combined, the six received at least $29 million from drug companies last year. The amount ranged from 2 percent to 7 percent of revenue at the Arthritis Foundation, to 89 percent to 91 percent at the much smaller National Gaucher Foundation. The funding usually comes from the companies' marketing or sales divisions, not charity offices. Grants often rise with promotional spending as a drug hits the market and fall when sales ebb. Donations from Merck and Pfizer Inc. to the Arthritis Foundation more than doubled, to at least $1.65 million combined, in 2000 as they launched Vioxx and Celebrex. Merck explicitly wove the foundation into sales strategies. In 2000-2001, the American Diabetes Association did not disclose an unusual gift from Lilly: a lent executive, Emerson "Randy" Hall Jr., who moved into its Alexandria, Va., headquarters and coached it on growth strategies, all paid by Lilly.

Note: If you want to understand how the huge pharmaceutical industry influences what you know about their drugs, this article is a must read. You may first want to read a riveting two-page summary of an exposé by the former editor-in-chief of the New England Journal of Medicine, who details major collusion and corruption in the pharmaceutical industry at http://www.WantToKnow.info/healthcoverup




The healing power of placebos
2006-05-01, Ode Magazine
http://www.odemagazine.com/article.php?aID=4294

A sugar pill, a salt solution, a doctor in a white jacket -- these all have the power to cure as long as the patient believes in their healing qualities. That seems impossible. So what does science say about the elusive placebo effect? Very little research has been done in this area of medicine. The pharmaceutical industry can’t profit; after all, they can’t make money from sugar pills. It is often forgotten that the effect could help people and shave billions off spiralling health-care costs. If researchers could gain more insight into how the effect works, it would stand as one of the biggest medical breakthroughs in history. Some people are convinced that the effect proves that strength of mind is sufficient to heal the body. Placebos have...proven successful in treating depression, anxiety, stress, warts and ulcers -- sometimes in as many as 60 to 70 percent of the cases. There are...objective effects everyone can measure. Placebo treatments have been shown to lower blood pressure and cholesterol levels as well as improve reaction speeds, pulse rates and immune-system activity. Ultimately, the placebo phenomenon points to a strange paradox in modern medical science. As soon as an alternative-health treatment proves successful, it is dismissed as the placebo effect. It works only because people believe in it. Yet this explanation appears to contradict one of the foundations of medical science, which stresses that the mind and body are separate, therefore ruling out the possibility of healing through belief.

Note: For ideas on why the placebo effect has rarely been studied, see our two-page health cover-up summary at http://www.WantToKnow.info/healthcoverup




A Serious Drug Problem
2005-05-06, New York Times
http://www.nytimes.com/2005/05/06/opinion/06krugman.html

Note: The following is the New York Times website's abstract of this article, which is a very good summary.

2003 Medicare bill is object lesson in how special interests hold America's health care system hostage; says law subsidizes private health plans, which have repeatedly failed to deliver promised cost savings, and creates unnecessary layer of middlemen by requiring that drug benefit be administered by private insurers; says it specifically prohibits Medicare from using its purchasing power to negotiate lower drug prices; notes that Rep Billy Tauzin, who shepherded drug bill through Congress, now heads all-powerful drug-industry lobbying group, and Thomas Scully, former Medicare administrator, negotiated for future health industry lobbying job at same time he was pushing drug bill; calls Medicare bill corrupt deal created by corrupt system.




Cold virus may be skin cancer cure
2004-01-07, CNN News
http://www.cnn.com/2004/HEALTH/01/07/australia.skincancer

Researchers at an Australian university believe they have developed a breakthrough showing skin cancer can be stopped by the common cold virus. Skin cancer, or melanoma, is the fifth most common form of cancer. Australia has the highest rate of melanoma in the world, with one out of every two people likely to develop some form of the disease during their lifetime. A team led by Professor Darren Shafren at the University of Newcastle, about 150 kilometers north of Sydney, have established that malignant melanoma cells can be destroyed by infecting them with coxsackievirus, the common cold virus. "We believe this is a significant breakthrough in the development of the treatment of melanoma," Dr Shafren said in a statement released by the university Wednesday. He said the results achieved so far using human cells and in animal studies had been "very exciting". "If we can replicate that success in human trials, the treatment of this often fatal disease could be available within the next few years," he said. According to the university researchers, the projected process begins by injecting the common cold virus into a melanoma. The virus replicates itself and then, according to the projection, begins killing off the melanoma. Within weeks, there is a reduction in the size of the melanoma and it eventually disappears. Dr Shafren noted that the coxsackievirus was not a manufactured drug or a genetically altered virus. Instead, it was a virus that occurred in the community.

Note: Why wasn't this exciting development put on the fast track and lots of money pored in to develop it quickly. Could it be that this cancer treatment would negatively impact the huge profits of the drug companies? For more reliable information on this, click here.




The Worms Crawl In
2008-07-01, New York Times
http://www.nytimes.com/2008/07/01/health/research/01prof.html?partner=rssuser...

While carrying out field work in Papua New Guinea in the late 1980s, [Dr. David Pritchard] noticed that Papuans infected with the Necator americanus hookworm, a parasite that lives in the human gut, did not suffer much from an assortment of autoimmune-related illnesses, including hay fever and asthma. Over the years, Dr. Pritchard has developed a theory to explain the phenomenon. "The allergic response evolved to help expel parasites, and we think the worms have found a way of switching off the immune system in order to survive," he said. "That's why infected people have fewer allergic symptoms." To test his theory, and to see whether he can translate it into therapeutic pay dirt, Dr. Pritchard is recruiting clinical trial participants willing to be infected with 10 hookworms each in hopes of banishing their allergies and asthma. Never one to sidestep his own experimental cures, Dr. Pritchard initially used himself as a subject. After Dr. Pritchard's self-infection experiment, the National Health Services ethics committee let him conduct a study in 2006 with 30 participants, 15 of whom received 10 hookworms each. Tests showed that after six weeks, the T-cells of the 15 worm recipients began to produce lower levels of chemicals associated with inflammatory response, indicating that their immune systems were more suppressed than those of the 15 placebo recipients. Despite playing host to small numbers of parasites, worm recipients reported little discomfort. Trial participants raved about their allergy symptoms disappearing.

Note: For lots of exciting reports on new health research, click here.




New Skin Cancer Treatment Saves Man
2008-06-18, CBS News/Associated Press
http://www.cbsnews.com/stories/2008/06/18/health/main4193276.shtml

A man who had been given less than a year to live had a complete remission of advanced deadly skin cancer after an experimental treatment that revved up his immune system to fight the tumors. The 52-year-old patient's dramatic turnaround was the only success in a small study, leading doctors to be cautious in their enthusiasm. However, the treatment reported in ... The New England Journal of Medicine is being counted as the latest in a small series of successes involving immune-priming treatments against deadly skin cancers. "Immunotherapy has become the most promising approach" to late-stage, death-sentence skin cancers, said Dr. Darrell Rigel, a dermatology researcher at the New York University Cancer Institute in New York. About 20 years ago, some scientists discovered that immune cells could latch onto and attack skin cancers. "There's a long history behind all of this," said Dr. Steven Rosenberg of the National Cancer Institute. In recent experiments, Rosenberg and other researchers have focused on souping up a certain kind of immune system cell - the "killer T cells" that envelop and kill foreign agents. Scientists focused ... on specific helper T cells that are adept at locking onto a cancer cell and guiding the killer cells to their target. The researchers drew blood from patients, located the special helper cells and then grew more of them in the laboratory. They then infused roughly 5 billion of the cells back into the patients without chemotherapy or the other harsh drugs. "It's a simpler and less toxic approach to melanoma than had been previously employed," said Dr. Louis Weiner, director of the cancer center at Georgetown University.

Note: For many hopeful reports on potential new cancer cures, click here.




Expect new drugs to treat aging, researchers say
2008-06-03, Atlanta Journal-Constitution/Cox News Service
http://www.ajc.com/services/content/health/stories/2008/06/03/anti_aging_drug...

Is 90 the new 50? Not yet, aging researchers say, but medical breakthroughs to significantly extend life and ease the ailments of getting older are closer than many people think. "The general public has no idea what's coming," said David Sinclair, a Harvard Medical School professor who has made headlines with research into the health benefits of a substance found in red wine called resveratrol. He said scientists can greatly increase longevity and improve health in lab animals like mice, and that drugs to benefit people are on the way. "It's not an if, but a when." Sinclair said treatments could be a few years or a decade away, but they're "really close. It's not something (from) science fiction and it's not something for the next generation." Robert Butler, a pioneer of aging research who won the Pulitzer Prize in 1976 for the book Why Survive? Being Old in America, [said] that "people live longer and better by having a sense of purpose." He said that while medicine and biology are important for longevity, having friendships and close relationships also have a big impact. Richard Weindruch, a professor at the University of Wisconsin ... studies how extremely low-calorie diets affect aging. Sinclair said that based on Weindruch's work, he set out a decade ago to find the genes involved in caloric restriction and find a pill that can provide the benefits "without you feeling hungry all the time." He described how his research found that mice given large doses of resveratrol "live longer, they're almost immune to the effects of obesity. They don't get diabetes, cancer, Alzheimer's as frequently. We delay the diseases of aging."




360 post-9/11 workers have died, including 80 of cancer
2008-05-08, New York Daily News
http://www.nydailynews.com/news/2008/05/08/2008-05-08_360_post911_workers_hav...

More than 360 workers who dealt with the aftermath of the World Trade Center disaster have died, state health officials said Wednesday. Officials have determined the cause of death of 154 of the responders and volunteers who toiled at Ground Zero, the blocks nearby and at the Fresh Kills landfill, where debris from the site was taken. Of those, 80 died of cancer. "It's the tip of the iceberg," said David Worby, who is representing 10,000 workers - 600 with cancer - who say they got sick after working on rescue and recovery efforts. "These statistics bear out how toxic that site was," Worby said. Most of the deadly tumors were in the lungs and digestive system, according to the tally from the state's World Trade Center Responder Fatality Investigation Program. Other deaths were traced to blood cancers and heart and circulatory diseases. Five ex-workers committed suicide, said Kitty Gelberg, who is tracking the deaths for the program. Gelberg said ... there is an overall undercount of workers who have died. Last year, the head of Mount Sinai Medical Center's monitoring and treatment program, Dr. Robin Herbert, predicted a "third wave" of 9/11-related deaths from cancer. Cathy Murray, whose husband, Fire Lt. John Murray, died of colon cancer April 30, "absolutely" connects his disease to his work at Ground Zero. He was diagnosed in June and was 52 when he died, she said. "He was perfectly healthy," said Cathy Murray, 53, of Staten Island. "He never smoked a day in his life, and neither did I. It happened so quick and so aggressive. He was responding at first, but then he wasn't," she added. "And now he's gone."

Note: For a powerful summary of reports from major media sources questioning the official story of what happened on 9/11, click here.




Why Hospitals Want Your Credit Report
2008-03-18, Wall Street Journal
http://online.wsj.com/article/SB120580305267343947.html

In a development that consumer groups say raises privacy issues, a growing number of hospitals are mining patients' personal financial information to figure out how likely they are to pay their bills. Some hospitals are peering into patients' credit reports, which contain information on people's lines of credit, debts and payment histories. Other hospitals are contracting with outside services that predict a patient's income and whether he or she is likely to walk away from a medical bill. Hospitals often use these services when patients are uninsured or have big out-of-pocket costs despite having health insurance. Consumer advocates say the practice creates the potential for hospitals to misuse the information by denying or cutting back on patients' care if they can't pay. What's more, hospitals could scour a patient's financial records for credit lines and encourage the patient to tap them, despite high interest rates or other costs. "It has the potential to put people at risk financially," says Mark Rukavina, executive director of the Access Project, a research and advocacy group that focuses on medical debt. The Health Insurance Portability and Accountability Act, or Hipaa, a federal law that has patient-privacy provisions, doesn't bar hospitals from providing patient payment histories to consumer reporting agencies. It's unclear how much latitude hospitals have to legally check a patient's financial information. Under the Fair Credit Reporting Act, hospitals are allowed to obtain patients' credit reports if they get their permission, says Rebecca Kuehn, an assistant director in the Federal Trade Commission's division of privacy and identity protection.

Note: For many other revelations of privacy abuses from reliable, verifiable sources, click here.




Food Allergies Stir a Mother to Action
2008-01-09, New York Times
http://www.nytimes.com/2008/01/09/dining/09alle.html?ex=1357534800&en=5584637...

[Robyn O’Brien's] story is one of several in a new book, Healthy Child, Healthy World. About two years ago, she fed her youngest child scrambled eggs. The baby’s face quickly swelled into a grotesque mask. Little Tory had a severe food allergy, and Ms. O’Brien’s journey had begun. Her theory — that the food supply is being manipulated with additives, genetic modification, hormones and herbicides, causing increases in allergies, autism and other disorders in children — is not supported by leading researchers or the largest allergy advocacy groups. [But] record numbers of parents are heading to doctors concerned that their children are allergic to a long list of foods. States are passing laws requiring schools to have policies protecting children with food allergies. No one knows why the number of allergies seems to be on the rise. Ms. O’Brien and leading allergy researchers agree that few reliable studies on food allergies exist. The best estimates suggest that 4 to 8 percent of young children suffer from them. Many health professionals, though, agree that something is changing. The hygiene hypothesis intrigues many researchers. It holds that children are being exposed to fewer micro-organisms and, as a result, have weaker immune systems. “But this alone cannot account for the massive relative increase in food allergy compared with other allergic disease such as asthma,” said Dr. Marc E. Rothenberg, the director of allergy and immunology at Cincinnati Children’s Hospital Medical Center. [Ms. O'Brien] chides top allergy doctors who are connected to Monsanto, the producer of herbicides and genetically modified seeds. She asserts that the Food Allergy and Anaphylaxis Network, the nation’s leading food allergy advocacy group, is tainted by the money it receives from food manufacturers and peanut growers.

Note: Visit Robyn O'Brien's website, AllergyKids.com. For many other powerful reports on health issues, click here.




HHS Toned Down Breast-Feeding Ads
2007-08-31, Washington Post
http://www.washingtonpost.com/wp-dyn/content/article/2007/08/30/AR20070830021...

In an attempt to raise the nation's historically low rate of breast-feeding, federal health officials commissioned an attention-grabbing advertising campaign a few years ago to convince mothers that their babies faced real health risks if they did not breast-feed. It featured striking photos of insulin syringes and asthma inhalers topped with rubber nipples. Plans to run these blunt ads infuriated the politically powerful infant formula industry, which hired a former chairman of the Republican National Committee and a former top regulatory official to lobby the Health and Human Services Department. Not long afterward, department political appointees toned down the campaign. The ads ran instead with more friendly images of dandelions and cherry-topped ice cream scoops, to dramatize how breast-feeding could help avert respiratory problems and obesity. In a February 2004 letter (pdf), the lobbyists told then-HHS Secretary Tommy G. Thompson they were "grateful" for his staff's intervention to stop health officials from "scaring expectant mothers into breast-feeding," and asked for help in scaling back more of the ads. The formula industry's intervention -- which did not block the ads but helped change their content -- is being scrutinized by Congress in the wake of last month's testimony by former surgeon general Richard H. Carmona that the Bush administration repeatedly allowed political considerations to interfere with his efforts to promote public health. "This is a credible allegation of political interference that [may] have had serious public health consequences," said [Rep. Henry] Waxman, a California Democrat. The milder campaign HHS eventually used had no discernible impact on the nation's breast-feeding rate, which lags behind the rate in many European countries.




F.D.A. Panel Votes to Keep Diabetes Drug on Market
2007-07-30, New York Times
http://www.nytimes.com/2007/07/30/health/30cnd-avandia.html?ex=1343448000&en=...

A federal drug advisory committee voted 20 to 3 late this afternoon that Avandia, a controversial diabetes drug made by GlaxoSmithKline, raises the risks of heart attacks, but it then voted 22 to 1 that the drug should nonetheless remain on the market. Dr. Clifford J. Rosen, chairman of the committee [said] “there was enough concern on the advisory committee that virtually everybody felt there was risk” of heart attacks from taking Avandia. Patients who have congestive heart failure or a history of cardiovascular disease, or those taking insulin or nitrates should not be given Avandia, Dr. Rosen said. The votes came after an extraordinary meeting in which officials from the Food and Drug Administration, which brought the committee together, openly disagreed with one another about the right course to take. Dr. David Graham, a drug safety officer at the F.D.A., called for the drug’s withdrawal and estimated that its toxic effects on the heart had caused as many as 205,000 heart attacks, strokes and death from 1999 to 2006. For every month that Avandia is sold, he said, another 1,600 to 2,200 patients are likely to suffer from heart attacks and strokes, some of them fatal. Dr. Robert Meyer, director of the office within the F.D.A. that approved Avandia’s initial application, immediately disagreed with Dr. Graham. Dr. Douglas C. Throckmorton, a deputy director of the F.D.A.’s center for drugs, explained at a news conference after the meeting that the split within the agency resulted from the “complexity” of the issue. The open disagreement within the F.D.A. reflects a fierce debate that has occurred among diabetes experts across the country since The New England Journal of Medicine published a study in May suggesting that Avandia increases the risks of heart attacks.

Note: To read a succinct, powerful summary of how drug companies control the regulation of their own industry, click here.




China corners vitamin market
2007-06-03, Seattle Times (One of Seattle's two leading newspapers)
http://seattletimes.nwsource.com/html/nationworld/2003732744_vitamins03.html

If you pop a vitamin C tablet in your mouth, it's a good bet it came from China. Indeed, many of the world's vitamins are now made in China. In less than a decade, China has captured 90 percent of the U.S. market for vitamin C, driving almost everyone else out of business. Chinese pharmaceutical companies also have taken over much of the world market in the production of antibiotics, analgesics, enzymes and primary amino acids. According to an industry group, China makes 70 percent of the world's penicillin, 50 percent of its aspirin and 35 percent of its [Tylenol], as well as the bulk of vitamins A, B12, C and E. In the wake of a pet-food scandal, in which adulterated wheat gluten from China led to the deaths of thousands of pets in North America, and other instances of food and toothpaste tampering, China's vitamin producers are reaching out to reassure U.S. consumers that their vitamins are safe. Whether that's true isn't clear, however. Foreign food-safety experts say China's larger companies have reputations to protect. The question is how they maintain quality control. Since U.S. laws don't require food and drug sellers to label products with the country of origin of ingredients, it's impossible for consumers to know where food or supplements are coming from, not to mention what factory produced them.




U.S. Issues Guidelines in Case of Flu Pandemic
2007-02-01, New York Times
http://www.nytimes.com/2007/02/01/health/01cnd-flu.html?ex=1327986000&en=0815...

Cities should close schools for up to three months in the event of a severe flu outbreak, ball games and movies should be canceled ... the federal government advised today in issuing new pandemic flu guidelines to states and cities. Health officials acknowledged that such measures would hugely disrupt public life, but they argued that these measure would buy the time needed to produce vaccines and would save lives. “We have to be prepared for a Category 5 pandemic,” said Dr. Martin Cetron, director of global migration and quarantine for the Centers for Disease Control and Prevention. “It’s not easy. The only thing that’s harder is facing the consequences.” The new guidelines also advocate having sick people and all their families' even apparently healthy members stay home for 7 to 10 days. Any pandemic is expected to move faster than a new vaccine can be produced. Current experimental vaccines against H5N1 avian flu are in short supply and based on strains isolated in 2004 or 2005. Although the government is creating a $4 billion stockpile of the antiviral drug Tamiflu, it is only useful when taken within the first 48 hours, and Tamiflu-resistant flu strains have already been found. The historian John Barry, author of “The Great Influenza,” a history of the 1918 flu, questioned an idea underpinning the study’s conclusions. There is evidence, he said, that some cities with low sickness and death rates in 1918 ... were hit by a milder spring wave of the virus. That would have, in effect, inoculated their citizens against the more severe fall wave and might have been more important than their public health measures.

Note: Why is it that government officials seem to want us to be afraid? Could it be that when we live in fear, we are more willing to give up our freedoms and money and allow them to be in control? For more, click here. And why would the government spend billions on stockpiling drugs of questionable use? For an answer, click here.




Eli Lilly accused of shaping drug guidelines
2006-10-18, MSNBC/Associated Press
http://msnbc.msn.com/id/15320680/

Several government doctors say drug maker Eli Lilly & Co. subtly orchestrated medical guidelines for treatment of an often lethal blood infection, hoping to boost sales of a drug whose value is being debated. “This company is trying to insinuate its drug into many aspects of patient care that industry really shouldn’t be involved in,” said Dr. Naomi O’Grady, a critical care specialist at the National Institutes of Health. Three of her NIH colleagues claim in Thursday’s New England Journal of Medicine that Lilly worked through medical societies to influence standards for treating the blood infection, sepsis. Ultimately, Xigris was incorporated into the guidelines. Both the guidelines committee and a larger information campaign on sepsis were heavily funded by [Lilly]. Dr. Phil Dellinger, who helped lead the guidelines committee, said...“We’ve been catching grief because we’ve been taking a lot of Lilly money — and we’re appreciative of Lilly giving it.” The U.S. Food and Drug Administration approved Xigris in 2001, despite an evenly split vote by its advisory committee. The lead author of Thursday’s journal article, Dr. Peter Q. Eichacker, voted against approval. Some critics are unhappy that the drug, which works only for the sickest patients, was approved on the basis of a single experiment. Academic officials acknowledged in the published guidelines that Lilly gave more than 90 percent of $861,000 in grants for the campaign and medical recommendations. O’Grady, of NIH, said a panel of disease experts that she headed refused to endorse the sepsis guidelines largely because Lilly “convened the whole panel.”

Note: For lots more on how the powerful pharmaceutical industry endangers our lives, click here.




A Windfall From Shifts to Medicare
2006-07-18, New York Times
http://www.nytimes.com/2006/07/18/business/18place.html?ex=1310875200&en=64d0...

The pharmaceutical industry is beginning to reap a windfall from a surprisingly lucrative niche market: drugs for poor people. The windfall, which by some estimates could be $2 billion or more this year, is a result of the transfer of millions of low-income people into the new Medicare Part D drug program that went into effect in January. Under that program...the prices paid by insurers, and eventually the taxpayer, for the medications given to those transferred are likely to be higher than what was paid under the federal-state Medicaid programs. Analysts expect it to generate hundreds of millions of additional dollars this year for the drug companies. Drugs tend to be cheaper under the Medicaid programs because the states are the buyers and by law they receive the lowest available prices for drugs. But in creating the federal Part D program, Congress -- in what critics saw as a sop to the drug industry -- barred the government from having a negotiating role. The windfall for the drug makers was made possible by a provision of the 2003 Medicare law that exempts Part D drugs from "best price" rebates that the drug makers have been required to give to the state Medicaid programs. Those rebates are meant to make sure that state Medicaid agencies pay no more than the best prices drug companies offer to any big commercial insurer. Now, under Part D, all sorts of price deals will be negotiated by dozens of Medicare drug plans. The prices will be reported to Medicare, but under a provision of the law pushed by industry lobbyists, they will otherwise be kept secret.




Judge Slams Ex-EPA Chief Over Sept. 11
2006-02-02, ABC/Associated Press
http://abcnews.go.com/US/wireStory?id=1574465

A federal judge blasted former Environmental Protection Agency chief Christine Todd Whitman on Thursday for reassuring New Yorkers soon after the Sept. 11 attacks that it was safe to return to their homes and offices while toxic dust was polluting the neighborhood. U.S. District Judge Deborah A. Batts refused to grant Whitman immunity against a class-action lawsuit brought in 2004 by residents, students and workers in lower Manhattan and Brooklyn who said they were exposed to hazardous materials from the destruction of the World Trade Center. "No reasonable person would have thought that telling thousands of people that it was safe to return to lower Manhattan, while knowing that such return could pose long-term health risks and other dire consequences, was conduct sanctioned by our laws," the judge said. She called Whitman's actions "conscience-shocking," saying the EPA chief knew that the collapse of the twin towers released tons of hazardous materials into the air. In her ruling, Batts noted that the EPA and Whitman said repeatedly beginning just two days after the attack that the air appeared safe to breathe. The EPA's internal watchdog later found that the agency, at the urging of White House officials, gave misleading assurances.




A new spin on the placebo effect
2005-11-28, MSNBC/Associated Press
http://www.msnbc.msn.com/id/10242034/

Research is showing the power of expectations, that they have physical -- not just psychological -- effects on your health. “Your expectations can have profound impacts on your brain and your health,” says Columbia University neuroscientist Tor Wager. Doctors have long thought the placebo effect was psychological. Now scientists are amassing the first direct evidence that the placebo effect actually is physical, and that expecting benefit can trigger the same neurological pathways of healing as real medication does. University of Michigan scientists injected the jaws of healthy young men with salt water to cause painful pressure, while PET scans measured the impact in their brains. During one scan, the men were told they were getting a pain reliever, actually a placebo. Their brains immediately released more endorphins -- chemicals that act as natural painkillers -- and the men felt better.




Despite Vow, Drug Makers Still Withhold Data
2005-05-31, New York Times
http://www.nytimes.com/2005/05/31/business/31trials.html?ex=1275192000&en=43d...

When the drug industry came under fire last summer for failing to disclose poor results from studies of antidepressants, major drug makers promised to provide more information about their research on new medicines. But nearly a year later, crucial facts about many clinical trials remain hidden. Eli Lilly and some other companies have posted hundreds of trial results on the Web and pledged to disclose all results for all drugs they sell. But other drug makers, including Merck and Pfizer, release less information and are reluctant to add more, citing competitive pressures. As a result, doctors and patients lack critical information about important drugs ... and the companies can hide negative trial results by refusing to publish studies, or by cherry-picking and highlighting the most favorable data. GlaxoSmithKline agreed to pay $2.5 million to settle a suit ... alleging that Glaxo had hidden results from trials showing that its antidepressant Paxil might increase suicidal thoughts in children and teenagers. Federal laws require the disclosure of all trials and trial results to the F.D.A. But companies are not required to disclose trial results to scientists or the public. Under pressure from the editors of medical journals, the major drug companies in January agreed to expand the number of trials registered on clinicaltrials.gov. Three companies have filed only vague descriptions of many studies, often failing even to name the drugs under investigation. For example, Merck describes one trial as a "one-year study of an investigational drug in obese patients."





Key Health News Articles in Major Media